Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

Overall, rates of new cancer diagnoses and cancer-related deaths have declined. Between 2018 and 2022, cancer death rates have decreased by 1.7% each year for men and 1.3% for women, the report stated ...

2 Pant, S et al. Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer: Overall Survival and Longer Follow-Up From the Phase 2b HERIZON-BTC-01 Study. J Clin Oncol. 2024; 42(16_suppl).

Gastrointestinal cancer refers to malignant conditions of the gastrointestinal (GI) tract and other organs involved in digestion, including the oesophagus, stomach, biliary system, pancreas ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

The application to the Ministry of Health, Labour and Welfare (MHLW) is set for a priority review, reflecting the relatively high incidence of biliary tract cancer in Japan relative to other ...

Biliary tract cancer is estimated to affect approximately 23,000 patients annually in the United States. The study enrolled 168 adult patients. All patients were dosed with 80 mg/m2 of paclitaxel ...

Overall cancer mortality rates decreased for men, women and children in the U.S. between 2018 and 2022, according to the National Cancer Institute’s “Annual Report to the Nation on the Status of ...

"This positive CHMP opinion is a welcome step for physicians and patients in Europe who face a critical unmet need in HER2-positive biliary tract ... difficult-to-treat cancer in the EU, marking ...

DUBLIN, April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...